Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 8, 2022 4:05 PM EDTReceived U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved $15.7 million in Q2 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesDosed first patient in Phase 3 VALIANT study in IC-MPGN and C3GCash and investments of $852.8 million as of June 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) --... More
